BLM and neoplasm: For BLM, one of three tumours exhibited definite biallelic inactivation through loss of the wildtype allele; a second tumour had possible biallelic inactivation, with a heterozygous somatic stop-gain variant observed (phase unknown); the remaining tumour however showed loss of the variant allele.